{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:23:57Z","timestamp":1769941437781,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006513","name":"Duke Clinical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006513","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ahj.2019.09.015","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T21:02:59Z","timestamp":1573246979000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction"],"prefix":"10.1016","volume":"220","author":[{"given":"Jay S.","family":"Shavadia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendimagegn","family":"Alemayehu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia M.","family":"Westerhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Povsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorin J.","family":"Brener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"van Diepen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Defilippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.09.015_bb0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ahj.2008.03.018","article-title":"Sp\\ontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments","volume":"156","author":"Bainey","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.09.015_bb0010","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.amjcard.2011.05.022","article-title":"Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials)","volume":"108","author":"Brener","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.amjcard.2015.09.043","article-title":"Factors associated with infarct-related artery patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the FAST-MI 2010 Registry)","volume":"117","author":"Bailleul","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0020","first-page":"136","article-title":"Impact of TIMI 3 patency before primary percutaneous coronary intervention for ST-elevation myocardial infarction on clinical outcome: results from the ASSENT-4 PCI study","volume":"1","author":"Zeymer","year":"2012","journal-title":"Eur Heart J Acute Cardiovas Care"},{"key":"10.1016\/j.ahj.2019.09.015_bb0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1160\/TH16-09-0712","article-title":"Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention","volume":"117","author":"Christopoulos","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2019.09.015_bb0030","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.015_bb0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.292.3.362","article-title":"Early vs late administration of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis","volume":"292","author":"Montalescot","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.09.015_bb0040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4244\/EIJV7I2A40","article-title":"A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis","volume":"7","author":"Rosencher","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2019.09.015_bb0045","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/eurheartj\/ehn125","article-title":"Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study","volume":"29","author":"Brener","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.09.015_bb0050","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jacc.2009.11.095","article-title":"Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease","volume":"55","author":"Gorog","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0055","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.09.015_bb0060","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/j.1538-7836.2012.04883.x","article-title":"An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values","volume":"10","author":"Pieters","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2019.09.015_bb0065","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jacc.2015.02.040","article-title":"Endogenous fibrinolysis: an important mediator of thrombus formation and cardiovascular risk","volume":"65","author":"Okafor","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002586","article-title":"Multimarker risk stratification in patients with acute myocardial infarction","volume":"5","author":"O'Donoghue","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2019.09.015_bb0075","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1161\/CIRCULATIONAHA.118.034125","article-title":"Use of biomarkers to predict specific causes of death in patients with atrial fibrillation","volume":"138","author":"Sharma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.015_bb0080","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J Ame Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0085","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cct.2008.06.003","article-title":"Integrating ancillary studies in a large clinical trial: The design and rationale of the APEX library","volume":"29","author":"Mahaffey","year":"2008","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ahj.2019.09.015_bb0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.297.1.43","article-title":"Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial","volume":"297","author":"Armstrong","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2019.09.015_bb0095","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ahj.2004.12.015","volume":"149","author":"Armstrong","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2019.09.015_bb0100","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity","volume":"9","author":"Assarsson","year":"2014","journal-title":"and excellent scalability. PloS One"},{"key":"10.1016\/j.ahj.2019.09.015_bb0105","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ahj.2019.09.015_bb0110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(06)68147-6","article-title":"Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial","volume":"367","author":"Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.09.015_bb0115","doi-asserted-by":"crossref","unstructured":"Ellis SG, Tendera M, de Belder MA, et al. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovas Interv 2009;2:909\u201316.","DOI":"10.1016\/j.jcin.2009.07.009"},{"key":"10.1016\/j.ahj.2019.09.015_bb0120","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","article-title":"Facilitated PCI in patients with ST-elevation myocardial infarction","volume":"358","author":"Ellis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.015_bb0125","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11239-016-1390-z","article-title":"Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction","volume":"42","author":"van Diepen","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ahj.2019.09.015_bb0130","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.ijcard.2013.01.004","article-title":"Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy","volume":"168","author":"van Diepen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0135","doi-asserted-by":"crossref","unstructured":"Gue YX, Gorog DA. Importance of endogenous fibrinolysis in platelet thrombus formation. Int J Mol Sci 2017;18(9).pii: E1850.","DOI":"10.3390\/ijms18091850"},{"key":"10.1016\/j.ahj.2019.09.015_bb0140","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2019.09.015_bb0145","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.thromres.2018.08.005","article-title":"The role of neutrophils in thrombosis","volume":"170","author":"Kapoor","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2019.09.015_bb0150","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Bruhl","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.ahj.2019.09.015_bb0155","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bcp.2011.11.003","article-title":"Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium","volume":"83","author":"Alam","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0160","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MOH.0000000000000001","article-title":"The potential of neutrophil elastase inhibitors as anti-inflammatory therapies","volume":"21","author":"Henriksen","year":"2014","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0165","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s004030050475","article-title":"TNF-alpha and serum induce SKALP\/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway","volume":"292","author":"Pfundt","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ahj.2019.09.015_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/15412555.2011.641803","article-title":"A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium","volume":"9","author":"Vogelmeier","year":"2012","journal-title":"COPD"},{"key":"10.1016\/j.ahj.2019.09.015_bb0175","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.rmed.2011.10.020","article-title":"AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide\/formoterol in patients with COPD","volume":"106","author":"Kuna","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.ahj.2019.09.015_bb0180","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.2169\/internalmedicine.49.4010","article-title":"A, Ohji G, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis","volume":"49","author":"Iwata","year":"2010","journal-title":"Intern Med"},{"key":"10.1016\/j.ahj.2019.09.015_bb0185","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/heartjnl-2015-307745","article-title":"Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial","volume":"101","author":"Alam","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2019.09.015_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1538-7836.2008.03220.x","article-title":"New insights into the molecular mechanisms of the fibrinolytic system","volume":"7","author":"Rijken","year":"2009","journal-title":"J Thrombo Haemost"},{"key":"10.1016\/j.ahj.2019.09.015_bb0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11064-017-2411-9","article-title":"Peroxynitrite-induced tyrosine nitration contributes to matrix metalloprotease-3 activation: relevance to hyperglycemic ischemic brain injury and tissue plasminogen activator","volume":"43","author":"Hafez","year":"2018","journal-title":"Neurochem Res"},{"key":"10.1016\/j.ahj.2019.09.015_bb0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000081102","article-title":"Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells","volume":"25","author":"Ghosh","year":"2004","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ahj.2019.09.015_bb0210","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/en.2009-0216","article-title":"Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator","volume":"150","author":"David","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.ahj.2019.09.015_bb0215","first-page":"695","article-title":"Pro- versus anti-inflammatory cytokines: myth or reality","volume":"47","author":"Cavaillon","year":"2001","journal-title":"Cell Mol Biol (Noisy-le-Grand)"},{"key":"10.1016\/j.ahj.2019.09.015_bb0220","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/01.CIR.0000155614.35441.69","article-title":"Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study","volume":"111","author":"Valgimigli","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.09.015_bb0225","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2004-03-1106","article-title":"Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes","volume":"105","author":"Lee","year":"2005","journal-title":"Blood"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031930273X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031930273X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:03:52Z","timestamp":1757570632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031930273X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"alternative-id":["S000287031930273X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.015","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}